Last year Doc stated that Euromed puts us years ahead of the competition. Assuming Euromed is still on target to be the second leg as Doc told us, the following page from the Euromed investor presentation could be a huge PR on its own. Especially the exclusive rights to distribute TLRY products in the EU. Hopefully we will know for sure in Q1 along with everything else.